Xeno Transplants Stock Performance
| XENO Stock | USD 0.0001 0.00 0.00% |
The firm maintains a market beta of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Xeno Transplants are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Xeno Transplants has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Xeno Transplants is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 2.5:1 | Last Split Date 2006-09-06 |
1 | United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service - StockTitan | 10/23/2024 |
2 | Glycorex products will be evaluated at military-affiliated centers in the US. - Marketscreener.com | 11/19/2024 |
| Total Cashflows From Investing Activities | -70.2 K |
Xeno |
Xeno Transplants Relative Risk vs. Return Landscape
If you would invest 0.01 in Xeno Transplants on September 14, 2024 and sell it today you would earn a total of 0.00 from holding Xeno Transplants or generate 0.0% return on investment over 90 days. Xeno Transplants is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Xeno, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Xeno Transplants Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xeno Transplants' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xeno Transplants, and traders can use it to determine the average amount a Xeno Transplants' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| XENO |
Based on monthly moving average Xeno Transplants is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xeno Transplants by adding Xeno Transplants to a well-diversified portfolio.
Xeno Transplants Fundamentals Growth
Xeno Stock prices reflect investors' perceptions of the future prospects and financial health of Xeno Transplants, and Xeno Transplants fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xeno Stock performance.
| Current Valuation | 363.27 K | ||||
| Price To Earning | 3.00 X | ||||
| Price To Book | 10.92 X | ||||
| Net Income | (256.37 K) | ||||
| Cash And Equivalents | 261 | ||||
| Total Debt | 21.56 K | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (6.56 K) | ||||
| Total Asset | 641.41 K | ||||
| Retained Earnings | (46.35 K) | ||||
| Current Asset | 100 K | ||||
| Current Liabilities | 1.05 M | ||||
About Xeno Transplants Performance
By examining Xeno Transplants' fundamental ratios, stakeholders can obtain critical insights into Xeno Transplants' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Xeno Transplants is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Xeno Transplants Corporation operates as a bio-technology research and development company. Xeno Transplants Corporation was incorporated in 2004 and is based in Brookline, Massachusetts. XENO TRANSPLANTS is traded on PNK Exchange in the United States.Things to note about Xeno Transplants performance evaluation
Checking the ongoing alerts about Xeno Transplants for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xeno Transplants help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xeno Transplants generated a negative expected return over the last 90 days | |
| Xeno Transplants has some characteristics of a very speculative penny stock | |
| Xeno Transplants currently holds 21.56 K in liabilities. Xeno Transplants has a current ratio of 0.15, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Xeno Transplants' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (256.37 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Xeno Transplants currently holds about 261 in cash with (6.56 K) of positive cash flow from operations. | |
| Latest headline from news.google.com: Glycorex products will be evaluated at military-affiliated centers in the US. - Marketscreener.com |
- Analyzing Xeno Transplants' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xeno Transplants' stock is overvalued or undervalued compared to its peers.
- Examining Xeno Transplants' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xeno Transplants' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xeno Transplants' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xeno Transplants' stock. These opinions can provide insight into Xeno Transplants' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeno Transplants. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Xeno Stock, please use our How to Invest in Xeno Transplants guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xeno Transplants. If investors know Xeno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xeno Transplants listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xeno Transplants is measured differently than its book value, which is the value of Xeno that is recorded on the company's balance sheet. Investors also form their own opinion of Xeno Transplants' value that differs from its market value or its book value, called intrinsic value, which is Xeno Transplants' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xeno Transplants' market value can be influenced by many factors that don't directly affect Xeno Transplants' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xeno Transplants' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xeno Transplants is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xeno Transplants' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.